Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

Disclosure William Camu has received consulting fees from Merck Serono, TEVA Pharma, and Sanofi-Aventis, and research grants from Bayer Schering, Biogen Idec, Merck Serono, TEVA Pharma, and Sanofi-Aventis. Sabine Latour is a salaried employee of Merck Serono S.A. – Geneva. Dieter Pohlau has received speaker fees from Bayer Schering Pharma, Teva, Aventis, and Biogen Idec. Karim Hadjout and Said Masri have no conflicts of interest to declare.